Journal Mobile Options
Table of Contents
Vol. 50, No. 1, 2004
Issue release date: June 2004
Neuropsychobiology 2004;50:16–20
(DOI:10.1159/000077936)

Association Study of –1727 A/T, –50 C/T and (CAA)n Repeat GSK-3β Gene Polymorphisms with Schizophrenia

Scassellati C. · Bonvicini C. · Perez J. · Bocchio-Chiavetto L. · Tura G.B. · Rossi G. · Racagni G. · Gennarelli M.
aGenetic Unit, bPsychiatric Rehabilitation Center IRCCS ‘San Giovanni di Dio’, Fatebenefratelli, and cDivision of Biology and Genetics, Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, dCenter of Neuropharmacology, Institute of Pharmacological Sciences, University of Milan, Milan, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3β in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position –1727 A/T and –50 C/T and a (CAA)n repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)3/(CAA)5 heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3β appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Innocenti GM, Ansermet F, Parnas J: Schizophrenia, neurodevelopment and corpus callosum. Mol Psychiatry 2003;8:261–274.
  2. Bunney BG, Potkin SG, Bunney WE Jr: New morphological and neuropathological findings in schizophrenia: A neurodevelopmental perspective. Clin Neurosci 1995;3:81–88.
  3. Chua SE, Murray RM: The neurodevelopmental theory of schizophrenia: Evidence concerning structure and neuropsychology. Ann Med 1996;28:547–555.
  4. Weinberger DR: On the plausibility of ‘the neurodevelopmental hypothesis’ of schizophrenia. Neuropsychopharmacology 1996;14:S1–S11.
  5. Arnold SE: Neurodevelopmental abnormalities in schizophrenia: Insights from neuropathology. Dev Psychopathol 1999;11:439–456.
  6. Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S, Anderton B, Everall I: Abnormalities of Wnt signalling in schizophrenia – evidence for neurodevelopmental abnormality. Neuroreport 1998;9:1379–1383.
  7. McMahon AP, Bradley A: The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell 1990;62:1073–1085.
  8. Moon RT, Brown JD, Torres M: WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997;13:157–162.
  9. Papkoff J, Aikawa M: WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem Biophys Res Commun 1998;247:851–858.
  10. Shaw PC, Davies AF, Lau KF, Garcia-Barcelo M, Waye MM, Lovestone S, Miller CC, Anderton BH: Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome 1998;41:720–727.
  11. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990;9:2431–2438.
  12. Leroy K, Brion JP: Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 1999;16:279–293.
  13. Brown JD, Moon RT: Wnt signaling: Why is everything so negative? Curr Opin Cell Biol 1998;10:182–187.
  14. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H: Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 1998;31:317–323.
  15. Phiel CJ, Wilson CA, Lee VM, Klein PS: GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 2003;423:435–439.
  16. Kozlovsky N, Belmaker RH, Agam G: Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000;157:831–833.
  17. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, Lovestone S, Anderton B, Everall I: Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001;302:117–120.
  18. Kozlovsky N, Belmaker RH, Agam G: GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 2002;12:13–25.
  19. Kozlovsky N, Belmaker RH, Agam G: Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 2001;52:101–105.
  20. Nadri C, Lipska BK, Kozlovsky N, Weinberger DR, Belmaker RH, Agam G: Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia. Brain Res Dev Brain Res 2003;141:33–37.
  21. Lau KF, Miller CC, Anderton BH, Shaw PC: Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics 1999;60:121–128.
  22. Russ C, Lovestone S, Powell JF: Identification of sequence variants and analysis of the role of the glycogen synthase kinase-3 beta gene and promoter in late onset Alzheimer’s disease. Mol Psychiatry 2001;6:320–324.
  23. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  24. Schneider S, Roessli D, Excofier L: Arlequin: A software for Population Genetics Data Analysis, ver 2.000. Geneva, University of Geneva, 2000.
  25. Sham PC, Curtis D: Monte Carlo tests for associations between disease and alleles at high polymorphic loci. Ann Hum Genet 1995;59:97–105.

    External Resources

  26. Kornman KS, Crane A, Wang HY, Di Giovine FS, Newman MG, Pirk FW, Wilson TG Jr, Higgenbottom FL, Duff GW: The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997;24:72–77.
  27. Quandt K, Frech K, Karas H, Wingender E, Werner T: MatInd and MatInspector: New fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878–4884.
  28. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Pruss M, Reuter I, Schacherer F: TRANSFAC: An integrated system for gene expression regulation. Nucleic Acids Res 2000;28:316–319.
  29. Maziade M, Roy MA, Rouillard E, Bissonnette L, Fournier JP, Roy A, Garneau Y, Montgrain N, Potvin A, Cliche D, Dion C, Wallot H, Fournier A, Nicole L, Lavallee JC, Merette C: A search for specific and common susceptibility loci for schizophrenia and bipolar disorder: A linkage study in 13 target chromosomes. Mol Psychiatry 2001;6:684–693.
  30. Le Coniat M, Sokoloff P, Hillion J, Martres MP, Giros B, Pilon C, Schwartz JC, Berger R: Chromosomal localization of the human D3 dopamine receptor gene. Hum Genet 1991;87:618–620.
  31. Beasley C, Cotter D, Everall I: An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res 2002;58:63–67.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50